How Do Retina Practices Protect Cash Flow When Buy-and-Bill Drug Inventory Is 35 to 50 Percent of Operating Cost?

What Actually Keeps Anti-VEGF Cash From Getting Stuck

The goal is simple: the money you fronted on a vial comes back fast and whole, and no injection claim quietly ages into a working-capital hole. Here is what does that, move by move.

1. Verify Benefits and Auth Before the Vial Is Opened

The most expensive mistake in buy-and-bill is injecting first and checking coverage second. Before each anti-VEGF injection, confirm the patient’s benefits, the drug’s authorization status, and any step-therapy or dosing limit the plan enforces. A vial opened against a claim that was never going to pay is a near-total loss, because biologics do not go back on the shelf. Catching a coverage gap the day before the visit is a reschedule; catching it after the injection is a write-off you already paid for.

2. Reconcile Every Vial Purchased Against Units Billed

Cash leaks in the gap between what you bought, what you injected, and what you actually billed and got paid. Match purchased vials to administered units to billed units to paid units, every cycle, so a vial that was used but never billed, or billed but underpaid, gets caught before it becomes a permanent loss. On a drug that can approach two thousand dollars a dose, a handful of unreconciled vials a month is real money walking out the door quietly, and reconciliation is the only thing that sees it.

3. Work Drug Denials and Records Requests the Day They Land

A records request on six injection claims is a hold on your cash, and holds only get longer when they sit. The moment a payer requests records or denies an injection claim, the response goes out: the note, the imaging, the medical necessity, packaged to the payer’s own requirement, not left in a queue. A denial worked the day it lands often clears in one cycle; the same denial worked three weeks late has already cost you a month of borrowed working capital on a drug you bought in advance.

4. Watch Every Injection Claim’s Aging Like a Cash Position

Injection claims are not ordinary receivables; each one is a vial of cash you already spent. Track every anti-VEGF claim by age, and escalate anything past 30 days before it becomes a line on your credit statement. When you can see, at a glance, which drug claims are aging and which payer is holding them, you stop discovering the hole at payroll and start closing it while it is still small. That visibility is what turns buy-and-bill from a cash gamble into a managed position.

5. Hand Injectable Claim Tracking to a Dedicated Team

Practices that stop covering payroll off a credit line do it by handing anti-VEGF claim tracking to a dedicated team: remote specialists who verify before the injection, reconcile every vial, and work drug denials the day they land, live in 1 to 2 weeks. The physicians go back to injecting and reading scans, a trained backup covers every gap, and the drug-claim queue stops being the thing that quietly drains the practice. Below is what it sounds like when nobody owns it yet, in providers’ own words.

Why This Keeps Happening

If the order and the injection were both right, why does the cash still get stuck? Because buy-and-bill shifts the drug acquisition risk onto the practice. You buy the vial, you administer it, and only then do you bill; the payer holds the money for as long as its review takes, and you have already paid the wholesaler. According to the American Academy of Ophthalmology, when some anti-VEGF agents approach two thousand dollars a dose, it does not take many unreimbursed or delayed claims to start pulling on the practice’s bottom line. The delay is not a nuisance; on this drug it is a working-capital event.

The scale is the second half of the problem. Industry guidance on retina practice finances describes injectable drug inventory as one of the largest cash commitments a retina practice makes, running as high as 35 to 50 percent of operating cost, with every vial in the refrigerator representing money already spent and not yet recovered. When a claim for that inventory lands in an aging queue that nobody owns full time, it competes with every other claim, and the ones worked first are rarely the six-figure drug claims sitting on a records request. Closing that gap is exactly what dedicated medical billing support is built to do.

And the cost is not only the delay. Biologics have a limited shelf life, so unused or expired stock is a direct loss, and a vial injected against a claim that later denies cannot be recovered at all. The American Academy of Ophthalmology notes that low margins mean neglecting even a handful of claims or underpayments can quickly reduce profitability. On buy-and-bill, a slow appeals process is not a billing backlog; it is the practice financing a payer’s review, drug loss, and underpayment leakage all at once, out of the same thin margin.

Most groups have already tried the obvious fixes before they talk to anyone. Each one fails the same way: the work lands back on the practice. The pattern, in one table:

The Solution

So what does “someone whose whole job it is” look like on a batch of held Eylea claims? The specialist starts before the injection ever happens: verifying benefits, authorization, and dosing limits so no vial is opened against a claim that cannot pay. Then they reconcile, matching purchased vials to administered, billed, and paid units each cycle, so the gap where cash leaks between the refrigerator and the remittance gets closed before it becomes a loss. Most buy-and-bill cash problems are a verification-and-reconciliation problem, and that is exactly what dedicated revenue cycle management is built to solve before it ever becomes a payroll scramble.

When a payer denies an injection claim or requests records, the specialist takes the delay off your cash. The response goes out the same day, the note and imaging and medical necessity packaged to that payer’s exact requirement, and the claim is tracked by age so it never quietly parks. Anything past 30 days gets escalated while it is still a small hole, not discovered at payroll as a large one. The physicians keep injecting; the money they fronted on the drug comes back on a schedule the practice can actually plan around.

Behind all of it, AI drafts the first pass and a credentialed human verifies. The workflow flags coverage gaps before the injection, assembles the records response, and tracks each claim’s aging; a person confirms the drug claim is right and owns every appeal and records request. Every security control that protects the chart and drug data moving through that process is documented and auditable, and the whole approach is described on our HIPAA and security page, because moving clinical and financial data through a claim workflow is only safe when the controls are real.

Who Actually Does This Work

Fair question: why would an outsourced team protect your drug cash better than your own billing staff? Because verifying anti-VEGF coverage and reconciling six-figure vial inventory is their entire day, not the thing they squeeze between check-ins. The people working your injection claims are credentialed medical professionals: overseas-trained physicians, US-licensed nurses and pharmacists, and PharmDs, all trained in US injectable-drug billing and buy-and-bill workflows. They know what a records request on a batch of Eylea claims actually needs, how to reconcile purchased vials against paid units, and how to work a drug denial so the cash comes back in one cycle. That is not a generalist task; it is a specialty.

We are not a call center. We are a clinical operations partner, a healthcare BPO built on dedicated virtual staff: 500+ credentialed professionals, 24/7 coverage, and the AI-first-pass plus human-verify workflow you just read about behind every one of them. A typical practice is live in 1 to 2 weeks, at up to 70% below the cost of hiring locally, and no one on our side goes out without a trained backup already inside your workflow, so a batch of held drug claims never sits because the one person who tracks them is on vacation.

And the security piece your compliance officer will ask about: we are audited to SOC 2 Type II with zero exceptions and certified for ISO/IEC 27001:2022, HIPAA, and GDPR, with zero breaches in eight years. Every workstation runs inside a secure enclave on US-based servers, with screen captures and downloads blocked by policy, so PHI never sits on someone’s home laptop. Every client account carries a $5M E&O and cyber liability policy and a BAA signed before any work starts; the full detail lives in our HIPAA and security posture.

Put the routine and the people together, and a specific list of things simply stops happening.

How We Permanently Fix the Process

A person alone is not the fix, and neither is a bot alone. The fix is a documented injectable-claim workflow: which payers manage which anti-VEGF drugs under what authorization and step rules, how each one wants records packaged, the reconciliation cadence that matches vials to paid units, and the aging escalation that flags a held claim before it becomes a credit-line draw. Before we take a single claim for a new practice, we chart your top drug denials and holds by payer and reason so we can see where the cash is actually getting stuck, and we build the workflow against that, not against a generic template.

From there the workflow becomes a living playbook rather than tribal knowledge in one coordinator’s head. It records how each payer wants medical necessity documented for an injection, which plans hold for records and how they release, the reconciliation steps that catch a used-but-unbilled vial, and the escalation path when a drug claim ages past 30 days. It is written down, kept current as payers change their rules, and owned by the team. When your specialist is out, a trained backup works the same playbook the same way, so a held injection claim never waits for one person to come back.

That is the difference between chasing this month’s held claims and fixing the process for good, and it is what a dedicated revenue cycle management partner actually buys you. A coordinator leaving used to mean the drug-claim queue fell apart and cash started getting stuck again. Under this model the workflow keeps running, the playbook stays, the backup steps in, and buy-and-bill stops being the thing that quietly drives you to the credit line.

The Whole Thing in Four Sentences

Retina practices lose cash on buy-and-bill because the practice fronts the drug and the payer controls when the money comes back, and on inventory that runs 35 to 50 percent of operating cost, every extra day in appeals ties up working capital you have already spent. Injecting first and checking coverage later, leaving drug claims in the general aging queue, and covering the gap from a credit line all fail the same way. The fix is to verify before the vial is opened, reconcile every vial to paid units, work denials and records requests the day they land, and watch each claim’s aging like the cash position it is. A retina group runs exactly this model with us today, names withheld, no patient data shown.

If you want to check us out before talking to anyone: our security posture is independently auditable, we are an MGMA 2026 Corporate Member, and 800+ providers run back office work with us.

Ready to stop financing the payer’s review? Try us risk free: two weeks, your real anti-VEGF claim queue, dedicated specialists verifying before the injection and working the drug denials, and if it does not earn the handoff, you walk away. From here down is the sales part, and it is short: here is exactly what it costs.

Written By

Dan Nandan

Founder and CEO, Staffingly, Inc. · Piscataway, NJ

Dan Nandan has spent 25+ years in IT consulting and healthcare BPO, was among the first in the US to build an RPO/BPO delivery network in India, and has been featured in Computerworld. He runs the operations and the dedicated virtual teams behind the workflows on this page; the team-voice answers above come from the remote specialists who work them every day.

Connect on LinkedIn

Where the Claims on This Page Come From